Associate Director, Scientific Publications

Associate Director, Scientific Publications Who We Are: Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team. What We Do: We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026. Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial. In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting, and continue to advance an early-stage pipeline of novel therapeutic candidates. In 2025, we initiated Phase 1 trials for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7). Nav1.7 and Kv7 are important pain targets, and data from these Phase 1 studies are expected in 2026 to support Phase 2 proof-of-concept studies in acute pain. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations. About the Role: We are seeking an Associate Director, Scientific Publications to take a hands-on role in shaping, driving, and executing publications for Xenon’s clinical stage programs. This role combines strategic thinking with operational excellence to ensure timely, high-quality, and compliant publications across congresses and journals. The incumbent will support publication planning, govern relationships with external agencies, provide day-to- day oversight of records within our publication management system, collaborate closely with authors and reviewers, and provide additional contributions to the Scientific Communications team as necessary. This position reports to the Director of Scientific Publications and involves forging close relationships with colleagues within Medical Affairs, Regulatory, Legal/Compliance, Value and Access, and Corporate Communications. This role will be based out of Boston, MA, USA in our Needham office. We will consider remote locations for exceptional candidates. Hybrid positions require a minimum of two onsite days per week. On-site positions require up to five on-site days per week. RESPONSIBILITIES: - Contribute to the design, refinement, and execution of integrated publication plans that align with Xenon’s development milestones, evidence needs, and competitive landscape - Apply program knowledge, core scientific messages, and lexicon foundations to ensure consistency across manuscripts, abstracts, posters, presentations, and publication extenders - Maintain a strong command of therapeutic landscapes, study designs, emerging data, and evolving evidence needs to ensure publication plans stay relevant and responsive - Integrate cross functi ... (truncated, view full listing at source)